BMS Primarycare — Medicare Part D spending
Rank #1 by attributed Part D spend · 18 tracked drugs · CMS data year 2023
About $19,594,167,559 of Medicare Part D spending in 2023 is attributed to BMS Primarycare across the 18 of its drugs tracked here, ranking it #1 among manufacturers on this site. Its biggest Part D drug is Eliquis at $18,273,451,967. Attribution uses the CMS manufacturer lists and is indicative, not definitive. These are aggregate program figures, not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
BMS Primarycare drugs in Medicare Part D (2023)
| Brand | Generic | Total spend | Per dosage unit | Beneficiaries | Spend rank |
|---|---|---|---|---|---|
| <a href="/drug/eliquis-apixaban/">Eliquis</a> | Apixaban | $18,273,451,967 | $9.74 | 3,927,848 | #1 |
| <a href="/drug/sprycel-dasatinib/">Sprycel</a> | Dasatinib | $510,233,995 | $444.79 | 5,120 | #103 |
| <a href="/drug/orencia-clickject-abatacept/">Orencia Clickject</a> | Abatacept | $451,311,111 | $1,402.17 | 10,895 | #121 |
| <a href="/drug/orencia-abatacept/">Orencia</a> | Abatacept | $178,400,675 | $1,386.44 | 4,032 | #252 |
| Orencia | Abatacept/Maltose | $53,626,257 | $1,415.91 | 1,749 | #591 |
| Opdivo | Nivolumab | $51,314,795 | $322.40 | 695 | #611 |
| Sotyktu | Deucravacitinib | $34,323,077 | $216.95 | 1,148 | #739 |
| Yervoy | Ipilimumab | $13,234,453 | $895.88 | 193 | #1120 |
| Evotaz | Atazanavir Sulfate/Cobicistat | $12,452,840 | $56.65 | 805 | #1153 |
| Nulojix | Belatacept | $5,270,868 | $991.09 | 269 | #1477 |
| Opdualag | Nivolumab-Relatlimab-Rmbw | $4,305,352 | $752.68 | 31 | #1556 |
| Baraclude | Entecavir | $2,808,858 | $37.09 | 250 | #1723 |
| Empliciti | Elotuzumab | $2,224,804 | $2,663.84 | 31 | #1803 |
| Reyataz | Atazanavir Sulfate | $958,844 | $40.47 | 76 | #2119 |
| Azactam | Aztreonam | $207,452 | $9.61 | 176 | #2617 |
| Kenalog-40 | Triamcinolone Acetonide | $25,718 | $1.04 | 945 | #3125 |
| Kenalog-80 | Triamcinolone Acetonide | $10,305 | $21.79 | 255 | #3279 |
| Kenalog-10 | Triamcinolone Acetonide | $6,188 | $1.30 | 190 | #3350 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Frequently asked questions
How much Medicare Part D spending does BMS Primarycare get?
In 2023, about $19,594,167,559 of Medicare Part D spending is attributed to BMS Primarycare across the 18 of its drugs tracked here. Its biggest is Eliquis at $18,273,451,967. This is gross program spending, not what patients pay. Source: CMS, data year 2023.
What is BMS Primarycare's top Medicare Part D drug?
Among the drugs tracked here, BMS Primarycare's highest Part D spending in 2023 is Eliquis at $18,273,451,967 (national rank #1 by total spend).
Is manufacturer attribution exact?
No. CMS may list multiple manufacturers per drug, and labeler relationships change over time. We attribute each drug to its primary listed manufacturer, so these rollups are indicative rather than definitive. Always check the underlying CMS file for a specific drug.
Keep exploring
Data: CMS Medicare Part D Spending by Drug (data year 2023), U.S. public domain. Aggregate program spending, not prices. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-21